vs
Side-by-side financial comparison of ImageneBio, Inc. (IMA) and Inventiva S.A. (IVA). Click either name above to swap in a different company.
ImageneBio, Inc. is a clinical-stage biotechnology company specializing in the development of precision oncology therapies and targeted radiopharmaceuticals for hard-to-treat cancers. It primarily serves the North American healthcare market, with a core focus on advancing personalized treatment options matched to patients’ unique genomic profiles.
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients living with fibrosis, rare diseases, and oncological conditions. It advances a pipeline of targeted product candidates, with key operations across Europe and North America, serving patient populations with high unmet medical needs worldwide.
IMA vs IVA — Head-to-Head
Income Statement — Q3 FY2025 vs Q2 FY2024
| Metric | | |
|---|---|---|
| Revenue | $0 | $5.1K |
| Net Profit | $-24.8M | $-49.0M |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | -961352.9% |
| Revenue YoY | — | — |
| Net Profit YoY | -678.5% | — |
| EPS (diluted) | $-2.91 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $0 | — | ||
| Q1 25 | $800.0K | — | ||
| Q3 24 | $3.5M | — | ||
| Q2 24 | — | $5.1K | ||
| Q4 23 | $658.0K | — | ||
| Q3 23 | $1.2M | — | ||
| Q2 23 | $2.0M | — | ||
| Q1 23 | $5.3M | — |
| Q3 25 | $-24.8M | — | ||
| Q1 25 | $-6.1M | — | ||
| Q3 24 | $-3.2M | — | ||
| Q2 24 | — | $-49.0M | ||
| Q4 23 | — | — | ||
| Q3 23 | $-17.3M | — | ||
| Q2 23 | $-17.1M | — | ||
| Q1 23 | $-14.2M | — |
| Q3 25 | — | — | ||
| Q1 25 | -1349.3% | — | ||
| Q3 24 | -58.2% | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | -1645.8% | — | ||
| Q2 23 | -922.7% | — | ||
| Q1 23 | -292.0% | — |
| Q3 25 | — | — | ||
| Q1 25 | -759.6% | — | ||
| Q3 24 | -90.9% | — | ||
| Q2 24 | — | -961352.9% | ||
| Q4 23 | — | — | ||
| Q3 23 | -1463.5% | — | ||
| Q2 23 | -854.0% | — | ||
| Q1 23 | -267.6% | — |
| Q3 25 | $-2.91 | — | ||
| Q1 25 | $-0.18 | — | ||
| Q3 24 | $-2.58 | — | ||
| Q2 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | $-0.40 | — | ||
| Q2 23 | $-0.44 | — | ||
| Q1 23 | $-0.39 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $142.6M | $11.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $139.8M | $-85.4M |
| Total Assets | $160.9M | $42.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $142.6M | — | ||
| Q1 25 | $114.1M | — | ||
| Q3 24 | $138.0M | — | ||
| Q2 24 | — | $11.0M | ||
| Q4 23 | $175.5M | — | ||
| Q3 23 | $196.9M | — | ||
| Q2 23 | $157.3M | — | ||
| Q1 23 | $137.8M | — |
| Q3 25 | $139.8M | — | ||
| Q1 25 | $-169.6M | — | ||
| Q3 24 | $-152.8M | — | ||
| Q2 24 | — | $-85.4M | ||
| Q4 23 | $-126.1M | — | ||
| Q3 23 | $155.3M | — | ||
| Q2 23 | $156.7M | — | ||
| Q1 23 | $135.0M | — |
| Q3 25 | $160.9M | — | ||
| Q1 25 | $130.8M | — | ||
| Q3 24 | $149.0M | — | ||
| Q2 24 | — | $42.6M | ||
| Q4 23 | $192.1M | — | ||
| Q3 23 | $215.3M | — | ||
| Q2 23 | $171.8M | — | ||
| Q1 23 | $152.4M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.6M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $-26.6M | — | ||
| Q1 25 | $-10.6M | — | ||
| Q3 24 | $13.0M | — | ||
| Q2 24 | — | — | ||
| Q4 23 | $-79.7M | — | ||
| Q3 23 | $-20.0M | — | ||
| Q2 23 | $-18.1M | — | ||
| Q1 23 | $-19.8M | — |
| Q3 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | $-80.2M | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | $-19.9M | — |
| Q3 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | -12181.9% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — | ||
| Q1 23 | -375.2% | — |
| Q3 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q4 23 | 62.9% | — | ||
| Q3 23 | 0.0% | — | ||
| Q2 23 | 0.0% | — | ||
| Q1 23 | 2.9% | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
